PMC4217353_01
Axial view of CT chest showed a peripheral consolidation (1.5 x 2 x 1 cm) and an apical cavitary lesion (2.5 x 3 x 3.5 cm) in the right upper lobe.
CRIPU2014-973573.001.jpg
PMC4217353_01_CRIPU2014-973573.001.jpg
fig1
The patient underwent chest computed tomography (CT) which was reported a pleura-based consolidated mass (1.5 x 2 x 1 cm) on the lateral aspect of the right upper lobe and a thick-walled cavitary lesion (2.5 x 3 x 3.5 cm) on the superomedial side of the right lung apex, highly suggestive of a Pancoast tumor (Figures 1 and 2).
Coronal view of CT chest showed a peripheral consolidation (1.5 x 2 x 1 cm) and an apical cavitary lesion (2.5 x 3 x 3.5 cm) in the right upper lobe.
CRIPU2014-973573.002.jpg
PMC4217353_01_CRIPU2014-973573.002.jpg
fig2
The patient underwent chest computed tomography (CT) which was reported a pleura-based consolidated mass (1.5 x 2 x 1 cm) on the lateral aspect of the right upper lobe and a thick-walled cavitary lesion (2.5 x 3 x 3.5 cm) on the superomedial side of the right lung apex, highly suggestive of a Pancoast tumor (Figures 1 and 2).
The 18F-FDG PET scan demonstrated hypermetabolic areas at the peripheral consolidation (SUV 7.4) and the apical cavitary mass (SUV 12.8) of the right upper lobe.
CRIPU2014-973573.003.jpg
PMC4217353_01_CRIPU2014-973573.003.jpg
fig3
It was followed by the 18F-FDG PET study, which demonstrated hypermetabolic uptake foci in these areas located within the right upper lobe (Figures 3 and 4).
The 18F-FDG PET scan demonstrated hypermetabolic areas at the peripheral consolidation (SUV 7.4) and the apical cavitary mass (SUV 12.8) of the right upper lobe.
CRIPU2014-973573.004.jpg
PMC4217353_01_CRIPU2014-973573.004.jpg
fig4
It was followed by the 18F-FDG PET study, which demonstrated hypermetabolic uptake foci in these areas located within the right upper lobe (Figures 3 and 4).
A follow-up CT chest after 6 weeks of antimycobacterial therapy revealed an interval resolution of the right pleura-based mass, and the right upper lobe cavity became thin-walled and much less prominent without new pulmonary lesions or lymphadenopathy.
CRIPU2014-973573.005.jpg
PMC4217353_01_CRIPU2014-973573.005.jpg
fig5
Serial CT chest imaging studies at the 6-week and the 6-month of antimycobacterial therapy revealed significant radiological improvement of pulmonary lesions (Figures 5 and 6).
Right pleural mass was almost resolved, and right apical cavitary lesion had significantly improved after 6 months of the triple drug therapy.
CRIPU2014-973573.006.jpg
PMC4217353_01_CRIPU2014-973573.006.jpg
fig6
Serial CT chest imaging studies at the 6-week and the 6-month of antimycobacterial therapy revealed significant radiological improvement of pulmonary lesions (Figures 5 and 6).
A follow-up CT chest at the end of the triple drug therapy showed a complete resolution of Mycobacterium kansasii pulmonary infection.
CRIPU2014-973573.007.jpg
PMC4217353_01_CRIPU2014-973573.007.jpg
fig7
The patient continued to improve clinically, and a total resolution of pulmonary lesions was achieved (Figure 7) on completion of a 12-month course of triple drug therapy.